Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer

International Journal of Biological Markers

Volumn 25, Issue 4, 2010, Pages 179-184

  Bennani, Bahia ^a   Gilles, Sophie ^b   Fina, Frederic ^b   Nanni, Isabelle ^b   Ibrahimi, Sidi Adil ^c   Riffi, Afaf Amarti ^a   Nejjari, Chakib ^a   Benajeh, Dafr Allah ^c   El Abkari, Mohammed ^c   Martin, Pierre Marie ^b,d   Ouafik, L'Houcine ^b,d  

^a Faculte de Medecine et de Pharmacie   (Morocco)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^c HASSAN II UNIVERSITY HOSPITAL   (Morocco)

^d INSERM   (France)

Author keywords

BRAF exon 15; Colorectal cancer; High resolution melting analysis; HRM; KRAS codons 12 and 13; Mutations

Indexed keywords

B RAF KINASE; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CODON; COLORECTAL ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MOROCCO; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; STEADY STATE;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; CODON; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MOROCCO; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SEQUENCE ANALYSIS, DNA;

EID: 78650843399     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2010.6091     Document Type: Article

References (34)

1. Downward J. Targeting RAS signalling pathways in cancer therapy. Nature Rev Cancer 2003; 3: 11-22.
2. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nature Rev Cancer 2007; 7: 295-308.
3. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nature Rev Cancer 2003; 3: 459-65.
4. Izumi Y, Kim S, Yoshiyama M, et al. Activation of apoptosis signal-regulating kinase 1 in injured artery and its critical role in neointimal hyperplasia. Circulation 2003; 108: 2812-8. (Pubitemid 37498985)
5. Baselga J, Rosen N. Determinants of RASistance to anti-epidermal growth factor receptor agents. J Clin Oncol 2008; 26: 1582-4.
6. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
7. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
8. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
9. O'Neill E, Rushworth L, Baccarini M, et al. Role of the kinase MST2 in suppression of apoptosis by the protooncogene product Raf-1. Science 2004; 306: 2267-70.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
11. Yuen ST, Davies H, Chan TL, et al. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res 2002; 62: 6451-5.
12. Domingo E, Espin E, Armengol M, et al. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 2004; 39: 138-42. (Pubitemid 38056086)
13. Li WQ, Kawakami K, Ruszkiewicz A, et al. BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status. Mol Cancer 2006; 5: 2.
14. Wojdacz TK, Dobrovic A. Methylation-sensitive high resolution melting (MS-HRM): a new approach for sensitive and high-throughput assessment. Nucleic Acids Res, 2007; 35: e41.
15. Harada K, Hiraoka S, Kato J, et al. Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features. Br J Cancer 2007; 97: 1425-31.
16. Barbacid M. ras genes. Ann Rev Biochem 1987; 56: 779-827.
17. Mor A, Philips MR. Compartmentalized Ras/MAPK signaling. Ann Rev Immunol 2006; 24: 771-800.
18. Singh A, Sowjanya AP, Ramakrishna G. The wild-type Ras: road ahead. FASEB J 2005; 19: 161-9.
19. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-34.
20. Smakman N, Borel Rinkes I H, Voest EE, et al. Control of colorectal metastasis formation by K-Ras. Biochim Biophys Acta 2005; 1756: 103-14. (Pubitemid 41773137)
21. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of Ras gene mutations in human colorectal cancers. Nature 1987; 327: 293-7.
22. Samowitz WS, Curtin K, Schaffer D, et al. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9: 1193-7.
23. Symvoulakis EK, Zaravinos A, Panutsopulos D, et al. Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. Int J Biol Markers 2007; 22: 12-8. (Pubitemid 46730029)
24. Miranda E, Destro A, Malesci A, et al. Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br J Cancer 2006; 95: 1101-7.
25. Einspahr JG, Martinez ME, Jiang R, et al. Associations of Kiras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics. Cancer Epidemiol Biomarkers Prev 2006; 15: 1443-50. Erratum in: Cancer Epidemiol Biomarkers Prev 2006; 15: 2016.
26. Chou LS, Lyon E, Wittwer CT. A comparison of high-resolution chromatography for mutation scanning: cystic fibrosis transmembrane conductance regulator gene as a model. Am J Clin Pathol 2005; 124: 330-8.
27. Takano EA, Mitchell G, Fox SB, et al. Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. BMC Cancer 2008, 8: 59.
28. Nomoto K, Tsuta K, Takano T, et al. Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. Am J Clin Pathol 2006; 126: 608-15. (Pubitemid 44498512)
29. Krypuy M, Newnham GM, Thomas DM, et al. High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer. BMC Cancer 2006; 6: 295.
30. Do H, Krypuy M, Mitchell PL, et al. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 2008, 8: 142.
31. Pichler M, Balic M, Stadelmeyer E, et al. Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors. J Mol Diagn 2009; 11: 140-7.
32. Ma ES, Wong CL, Law FB, et al. Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J Clin Pathol 2009; 62: 886-91.
33. Chang YS, Yeh KT, Chang TJ, et al. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 2009, 9: 179.
34. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Medicine 2008; 359: 1757-65.